{"id":6907,"date":"2023-08-23T06:00:00","date_gmt":"2023-08-23T06:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/"},"modified":"2023-08-23T06:00:00","modified_gmt":"2023-08-23T06:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-juni-2023","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2023"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Stark preklinisk framdrift med NEX-22, positiva fas 1-data med NEX-20 och flera partnerprojekt i preklinisk utv\u00e4rdering<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>V\u00e4sentliga h\u00e4ndelser under andra kvartalet 2023<\/p>\n<ul>\n<li>Nanexa AB meddelade i juni att rekrytering och dosering har slutf\u00f6rts i Fas 1-studien med NEX-20. Sedan december 2022 har friska frivilliga administrerats singeldoser i tre p\u00e5 varandra f\u00f6ljande eskalerande dosgrupper. Data f\u00f6r farmakokinetisk profil, s\u00e4kerhet och tolerabilitet har samlats in f\u00f6r den sista dosgruppen och resultat f\u00f6rv\u00e4ntas presenteras under h\u00f6sten.<\/li>\n<li>Nanexa skrev avtal med kontraktsforskningsbolaget (CRO) Profil i Neuss, Tyskland, inf\u00f6r den kommande fas I-studien med NEX-22, en m\u00e5nadsdep\u00e5 av liraglutid f\u00f6r behandling av typ 2-diabetes och i f\u00f6rl\u00e4ngningen \u00e4ven obesitas (fetma). Profil \u00e4r h\u00f6gspecialiserat p\u00e5 tidiga kliniska studier inom diabetes och obesitas och har ett utm\u00e4rkt globalt anseende f\u00f6r sitt genomf\u00f6rande av klinisk forskning inom dessa b\u00e5da indikationer.<\/li>\n<\/ul>\n<p>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/p>\n<ul>\n<li>Nanexa erh\u00f6ll i augusti farmakokinetiska data fr\u00e5n den kliniska Fas 1-studien med NEX-20 som konfirmerade tidigare prekliniska resultat och visade en fris\u00e4ttningsprofil av lenalidomid i olika doser upp till 21 dagar. Slutliga data p\u00e5 s\u00e4kerhet och tolerabilitet f\u00f6rv\u00e4ntas i oktober och hittills rapporterade lokala biverkningarna med NEX-20 har varit begr\u00e4nsade och \u00f6verg\u00e5ende.<\/li>\n<li>Nanexa meddelade att en ny preklinisk studie av NEX-22 i minigrisar bekr\u00e4ftar en l\u00e5ng fris\u00e4ttningsprofil av liraglutid, vilket tidigare setts i r\u00e5tta. Data visar att en fris\u00e4ttningsprofil av NEX-22 kan erh\u00e5llas i minst 28 dagar vilket var den farmakokinetiska studiens l\u00e4ngd och m\u00e5let med studien.<\/li>\n<\/ul>\n<p>Sammanfattning av rapportperioden 1 april \u2013 30 juni 2023<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 7 655 (211) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -10 067 (-15 854) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -9 951 (-16 224) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,16 (-0,32) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -22 141 (-20 822) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 38 358 (66 904) kSEK<\/li>\n<\/ul>\n<p>Sammanfattning av rapportperioden 1 januari \u2013 30 juni 2023<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 15 828 (509) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -18 770 (-28 185) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -18 553 (-28 594) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,31 (-0,56) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -42 824 (-38 756) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 38 358 (66 904) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida: <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" rel=\"noopener\" target=\"_blank\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p><strong>Rapportkommentar 23 augusti kl 11:00<\/strong><br \/>En lives\u00e4nd kommentar med vd David Westberg och styrelseordf\u00f6rande G\u00f6ran Ando h\u00e5lls den 23 augusti kl. 11:00 via Infront Direkt Studios och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p><a href=\"https:\/\/www.youtube.com\/watch?v=idJw5sn6P8U\" rel=\"noopener\" target=\"_blank\">Rapportkommentaren kommer att finnas tillg\u00e4nglig h\u00e4r.<\/a><\/p>\n<p>Rapportkommentaren kommer \u00e4ven att l\u00e4ggas upp p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2023-08-23 08:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/394cd2df-772b-4d21-a940-7a557222fb5b\/nanexa-delarsrapport-jan-jun-2023.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa Del\u00e5rsrapport Jan Jun 2023<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Stark preklinisk framdrift med NEX-22, positiva fas 1-data med NEX-20 och flera partnerprojekt i preklinisk utv\u00e4rdering<\/p>\n","protected":false},"template":"","class_list":["post-6907","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q2_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2023 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2023 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Stark preklinisk framdrift med NEX-22, positiva fas 1-data med NEX-20 och flera partnerprojekt i preklinisk utv\u00e4rdering\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2023 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2023-08-23T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2023 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2023 - Nanexa AB","og_description":"Stark preklinisk framdrift med NEX-22, positiva fas 1-data med NEX-20 och flera partnerprojekt i preklinisk utv\u00e4rdering","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2023 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2023-08-23T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2023"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}